Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS20070005083 A1
Type de publicationDemande
Numéro de demandeUS 11/515,181
Date de publication4 janv. 2007
Date de dépôt1 sept. 2006
Date de priorité30 avr. 1997
Autre référence de publicationEP1157663A1, US7670373, US8136520, US20100114157, WO1998048706A1
Numéro de publication11515181, 515181, US 2007/0005083 A1, US 2007/005083 A1, US 20070005083 A1, US 20070005083A1, US 2007005083 A1, US 2007005083A1, US-A1-20070005083, US-A1-2007005083, US2007/0005083A1, US2007/005083A1, US20070005083 A1, US20070005083A1, US2007005083 A1, US2007005083A1
InventeursSabaratham Sabanathan, Thirumani Sabanathan
Cessionnaire d'origineSabaratham Sabanathan, Thirumani Sabanathan
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Occlusion device
US 20070005083 A1
Résumé
An obturator for a bronchial tube or tubule of a human or animal lung comprises a blocking element (92) and a securing element (90). The blocking element serves to seal the tube or tubule against the passage of fluid past the obturator when the obturator is disposed in a bronchial tube or tubule. The securing element serves to retain the blocking element in position. The blocking element comprises a substantially cylindrical plug of biocompatible, resiliently deformable closed-cell foamed plastics material, such as PVC. The securing element comprises a stent having barbs (98) to engage and retain the blocking element. The stent also has anchors (100) to retain the stent in a bronchial tube or tubule. A method of treatment of emphysema or other lung conditions or diseases in human or animal patients comprises placing an obturator in a bronchial tube or tubule of the patient so as to seal the tube or tubule against the passage of fluid past the obturator.
Images(4)
Previous page
Next page
Revendications(9)
1. A method of treating a lung, comprising:
providing a flow control device, the flow control device comprising a frame adapted to self-expand from a contracted configuration to an expanded configuration, the frame coupled to a membrane;
inserting the flow control device in a bronchial passageway such that the frame self-expands within the bronchial passageway and the membrane seals with a wall of the bronchial passageway so that the flow control element prohibits air from flowing past the flow control element in an inhalation direction within the bronchial passageway and also prohibits air from flowing past the flow control element in an exhalation direction within the bronchial passageway.
2. A method as in claim 1, wherein the flow control device has a proximal end and a distal end, and wherein a transverse dimension of the flow control device is greatest at a location in between the proximal end and the distal end.
3. A method as in claim 1, wherein the flow control device has a proximal end and a distal end, and wherein a diameter of the flow control device at a location between the proximal and distal ends is greater than the diameters at the proximal end and at the distal end.
4. A method as in claim 1, wherein the flow control device has a largest diameter at a location between proximal and distal ends of the flow control device.
5. A method as in claim 1, wherein a diameter of the flow control device undergoes an increase moving from a distal end of the flow control device toward a proximal end of the flow control device, and wherein the diameter also undergoes a decrease moving from the distal end toward the proximal end.
6. The method of claim 1, wherein the membrane forms an air tight seal with a wall of the bronchial passageway.
7. The method of claim 1, wherein the flow control device self-expands in a manner such the flow control device has an enlarged diameter at a location between proximal and distal ends of the flow control device.
8. The method of claim 1, wherein the frame includes at least one anchor and wherein the at least one anchor attaches to the wall of the bronchial passageway.
9. The method of claim 1, further comprising:
inserting a delivery tube into the bronchial passageway, the delivery tube loaded with the flow control device; and
guiding the delivery tube to a location within the bronchial passageway prior to releasing the flow control element.
Description
  • [0001]
    This application is a continuation of co-pending U.S. patent application Ser. No. 09/762,692, entitled “Occlusion Device”, filed Oct. 31, 2005, which is the National Stage of International PCT Application No. PCT/GB98/00652, entitled “Occlusion Device”, filed Mar. 3, 1998, which claims the benefit of priority to U.K. Patent Application No. 9708681.3, entitled “Lung Treatment Device”, filed Apr. 30, 1997. Disclosures of the aforementioned patent applications are hereby incorporated by reference in their entirety.
  • SUMMARY
  • [0002]
    The present invention relates to a device useful in the treatment of emphysema and other diseases or disorders of the human or animal lung.
  • [0003]
    Emphysema is a disease of the lung caused primarily by prolonged smoking, although not exclusively thereby. It is an unrelentless, intractable and debilitating process. Emphysema is defined as an abnormal permanent enlargement of the air spaces distal to the terminal bronchioles, accompanied by destruction of their walls without obvious fibrosis. In this context, destruction means non-uniformity in the pattern of respiratory,airspace enlargement; orderly appearance of the acinus is disturbed and may be lost.
  • [0004]
    Emphysema causes a physiological loss of lung elastic recoil, which decreases expiratory airflow by loss of driving pressure and premature airway closure from reduced airway traction. The effect of this is that the alveoli become hyper-inflated without there being any real exchange of air with the outside. Therefore the patient begins to feel starved of oxygen and so attempts to breathe more deeply. In breathing more deeply, the effects are exacerbated.
  • [0005]
    Not only are those individual alveoli which have a block in their respective bronchial tubules affected, but also neighbouring alveoli, perhaps in other regions of the lung, which may otherwise be perfectly serviceable, become affected because the hyper-inflated alveoli pressurise neighbouring alveoli and prevent them from expanding fully. There is, of course, a relatively fixed “exchange” volume of an individual's lung, that is to say, the difference between the expanded volume and the deflated volume. Emphysema reduces the exchange volume because undeflated alveoli occupy that space. Consequently, the only recourse available to the patient is to increase the expanded volume, thereby resulting in the barrel chest symptomatic of emphysema sufferers.
  • [0006]
    The major therapeutic modalities currently available consist of bronchodilator and anti-inflammatory drugs, directed at decreasing airway resistance, and antibiotics to treat acute and chronic infection. Supplemental oxygen therapy for the hypoxaemic patient improves exercise performance and improves survival in patients with cor pulmonale. Despite all available medical therapies, the course of the disease is one of progressive limitation, increasing dyspnoea and significant increase in overall mortality.
  • [0007]
    It has long been realised that full lung volume is more than enough for survival in most circumstances and that a person can survive quite satisfactorily with only one lung, for example. Heterogenous distribution of emphysema, together with the lack of pulmonary blood flow to those areas have made lung volume reduction surgery a logical option. Removal of parts of the lung affected by emphysema permits unaffected areas to become operative again and so enable a better quality of life for the patient. Clearly, however, such invasive procedures are of a very serious nature and some patients will not, in any event, be in a sufficiently strong condition to accept the trauma of such procedures. Primarily, the basic relief for emphysema sufferers is inactivity, on the one hand, and breathing pure oxygen, on the other.
  • [0008]
    Emphysema is a distressing condition affecting a relatively large proportion of the population, and a more effective and less traumatic treatment is required.
  • [0009]
    On a different matter, other lung conditions sometimes lead to bleeding into the lung. A patient having this condition feels movement of the blood caused by airflow in the lung during breathing, and perceives the blood as a foreign body and irritant. The patient coughs in an attempt to dislodge the perceived foreign body. Coughing blood, of course, is sometimes the first warning of a more serious disease or condition, but once that is realised, there is no benefit in such bleeding. Moreover, in such conditions where the lung might heal itself and subsequently stop bleeding, or indeed simply where the bleeding needs to be confined, the coughing reaction, which is almost impossible to resist, does not help the situation at all, and merely spreads the blood to other areas of the lung.
  • [0010]
    U.S. Pat. No. 5,382,261 discloses a vessel occluder for providing permanent occlusion of a vessel in a person by use of a flexible closure member attached to at least one radially expandable stent. The occluder does not have barbs or anchors or a stent.
  • [0011]
    DE-U-9205797 discloses a self expanding ‘meshbasket’ for the occlusion of human hollow organs. The invention is directed to female contraceptive devices and addresses the problem of remaining in place. The device may also find application in embolism therapy and vascular occlusion.
  • [0012]
    WO-A-9532018 discloses a body passageway closure for use in the occlusion of various passageways within the body, with particular application for the occlusion of blood vessels.
  • [0013]
    Therefore it is an object of the present invention to provide a method of treatment of certain lung conditions or diseases and to provide a device for such treatment.
  • [0014]
    In accordance with a first aspect of the present invention there is provided a method of treatment of emphysema or other lung conditions or diseases, the method comprising placing an obturator in a bronchial tube or tubule so as to seal the tube or tubule against the passage of fluid past the obturator.
  • [0015]
    In the case of emphysema, and by the simple expedient of inserting an obturator in a bronchial tube, a section of a lung can be isolated so that no air can be drawn into it. Thereafter, the isolated part deflates in time as the air remaining in it becomes absorbed, and so that part of the lung stops affecting other areas of the lungs, which can thus perform normally. Such a procedure is relatively simple, requiring only a delivery device for the obturator, which device is inserted through the mouth and airway of the patient until the proposed placement site is reached, whereupon the device is activated to release the obturator from the device.
  • [0016]
    In the case of bleeding into the lung, an obturator stops the flow of blood. The lung is tamponated by the obturator and blood merely collects in the isolated part of the lung and ultimately, if the bleeding stops, will be reabsorbed. Alternatively, in the case of some, perhaps terminal, conditions such as some lung cancers, it at least provides temporary relief for the patient.
  • [0017]
    In accordance with a second aspect of the invention there is provided the use of a blocking element and a securing element in the manufacture of an obturator for use in the treatment of a lung condition in a human or animal by blocking a bronchial tube or tubule. The condition may be emphysema.
  • [0018]
    Preferably the two elements are separate components, the blocking element serving to seal the tube or tubule against the passage of fluid past the obturator when the obturator is disposed in a bronchial tube or tubule, and the securing element serving to retain the blocking element in position in the tube or tubule.
  • [0019]
    The blocking element preferably comprises a substantially cylindrical plug of biocompatible material. The plug may comprise resiliently deformable closed-cell foamed plastics material, such as PVC, so that it may be compressed to facilitate insertion into the tube or tubule and thereafter expand to fill the cross-section of the tube or tubule.
  • [0020]
    It is known to employ stents in medical fields to expand and support collapsed blood vessels, and indeed bronchial tubes. A stent is a compressible framework which, when inserted into a vessel and released, expands and, within the limits of its expansion, supports and possibly expands the walls of the vessel.
  • [0021]
    Preferably, the securing element comprises a stent. The stent may have barbs to engage and retain the blocking element. The stent preferably also has anchors to retain the stent in a bronchial tube or tubule.
  • [0022]
    In one embodiment, the stent comprises a crown of surgical quality steel wire legs in zig-zag formation. Said barbs and anchors may depend from points of the crown. Preferably the crown is closed in its circumference, although this is not essential.
  • [0023]
    In another embodiment, the stent comprises a dome of surgical quality steel wire legs. Said barbs and anchors may be formed on the ends of said legs.
  • [0024]
    It is known in medical fields to block blood vessels, for example where a genetic or other defect has resulted in a hole which needs blocking, or, for example, in the case of babies whose aortic to pulmonary artery connection has not closed following birth, a condition known as patent ductus arteriosus. In the case of holes, it is well known to employ an “umbrella”, where a diaphragm of material forms the seal against the blood vessel wall, the handle of the umbrella serving to keep the diaphragm across the vessel. In the case of babies, it has also been known to employ a plug of PVC foam to treat patent ductus arteriosus, the plug encouraging clotting.
  • [0025]
    However, in the case of bronchial tubes and tubules a diaphragm seal has not been used yet, although its application cannot be entirely ruled out. For example, an umbrella device with a larger surface area of contact with the bronchial mucosa might be as effective.
  • [0026]
    In blood vessels a complete seal is seldom required because any leak soon blocks by the formation of a clot; something that would not happen in an airway of a lung. Secondly, airways are not always absolutely circular in section, so a circular diaphragm may not always make a good seal, at least around some parts of the circumference, unless it has capacity to expand in all radial directions and has a large contact area.
  • [0027]
    However, a complete seal is an absolute requirement of the present invention (at least over the period of a single breath), because without it, air can leak past during inhalation and pressurise the lung in just the same way, and perhaps even to a greater extent. More importantly, however, a patient with such an obturator in place can only feel its presence if there is movement of air around it to stimulate adjacent nerve endings. Once a patient can feel the obturator, there will be irresistible compulsion to cough which, if done excessively, may be sufficient to dislodge the obturator.
  • [0028]
    Thus it has been found that a very effective seal is achieved by the use of said cylindrical plug of foamed PVC (of the type commonly employed as earplugs). The effectiveness of this arrangement is probably due to the fact that any leakage path has to be a long one and there are thus numerous opportunities for it to close and seal about at least one closed circuit around the plug. Another reason is that a plug can mould itself to the shape of the tube or tubule, which is itself unlikely to be cylindrical, or, indeed, circular in cross-section.
  • [0029]
    Preferably, the method of the present invention employs an obturator of the type defined above.
  • [0030]
    The delivery device preferably comprises a delivery tube in which the obturator is received in a compressed state at a distal end thereof, a guide tube, which is capable of following a possibly tortuous path under the guidance of a surgeon from entry into the mouth of a patient, down the patient's trachea and one bronchus to a proposed delivery site in a bronchial tube or tubule, and which has a passage to receive the delivery tube therealong, and release means to eject the obturator from the delivery tube and guide tube.
  • [0031]
    The obturator needs to slide in the delivery tube during ejection and the stent provides a low friction surface of the obturator to facilitate such ejection.
  • [0032]
    It is feasible that the blocking and securing elements may be integrally formed from plastics material, and wherein the securing element comprises adhered or fused anchor elements on the blocking element.
  • [0033]
    It is also feasible that the securing element may comprise a memory metal which is released to its normal expanded shape by a physical parameter, for example, the passage of an electric current therethrough, once it has been inserted at the proposed location. Otherwise it is in the same form as the above described steel stent which relies on resilience for its expansion. The advantage of a memory metal device is that it requires no compression during insertion so that the delivery tube of the delivery device may be replaced by a simple guide rod to which it is connected.
  • DESCRIPTION OF DRAWINGS
  • [0034]
    The invention will be better understood from the following description of particular embodiments given as non-limiting examples. The description refers to the accompanying drawings, in which:
  • [0035]
    FIG. 1 shows a section through the human chest indicating the location of bronchial obturators in the lungs;
  • [0036]
    FIG. 2 shows a bronchial obturator complete with delivery system;
  • [0037]
    FIGS. 3 a b and c show in perspective two embodiments of an obturator according to the present invention, that of FIG. 3 a having a crown stent, and that of FIG. 3 b having a dome stent, FIG. 3 c being a crown stent in an open configuration prior to rolling and, optionally, welding into a ring as in FIG. 3 a;
  • [0038]
    FIGS. 4 a and b show an internal barb and external anchor respectively;
  • [0039]
    FIG. 5 is a perspective view of another embodiment of obturator in accordance with the present invention; and,
  • [0040]
    FIG. 6 is a perspective view of yet another embodiment of obturator also in accordance with the present invention.
  • DETAILED DESCRIPTION
  • [0041]
    In FIG. 1 of the drawings, a human chest cavity 10 includes a pair of lungs 12 which each comprise upper and lower lobes 14,16. A trachea 18 branches into two bronchi 20, which further branch into bronchial tubes 22 and segmental bronchi 24. The bronchi 24, after further branching, terminate in alveoli 26.
  • [0042]
    In the majority of patients suffering from emphysema, it frequently effects mainly the upper lobes 14 of the lungs, leaving the lower lobes 16 unaffected, or at least less affected. However, if no treatment is given to a patient, the expansion effect of the upper lobes as the condition develops presses on the lower lobes and reduces their capacity to perform efficiently. Lower lobe emphysema does occur in some patients, and in which event it is then the upper lobes which are compressed.
  • [0043]
    Thus the present invention suggests placing an obturator 50 in a bronchial tube or tubule to isolate the region of the lung supplied by that tube or tubule. Where the obturator is placed will be decided by the surgeon and will depend on the how localised the damaged region of lung is. That is to say, if the whole lobe is badly affected, then the obturator is placed in the lobar bronchus 22 supplying that lobe (as shown at 50 in FIG. 1). On the other hand, if the damage is more localised, then the obturator will be placed in a smaller segmental bronchus 24, (as shown at 50′ in FIG. 1). Thus more than one obturator may be employed in the same pair of lungs isolating different regions of them. They will also be of different sizes, depending where they are to be inserted.
  • [0044]
    The above considerations equally apply when the condition being treated is not emphysema but some other condition which a doctor considers can usefully be treated by the method of the present invention. Such another condition is where a lung, or part of it is bleeding into the airway and an obturator isolates the bleeding region and inhibits coughing which may damage the lung further, or at least cause further discomfort to the patient.
  • [0045]
    FIG. 2 shows an endo-bronchial obturator 50 complete with delivery device 70. The delivery device comprises a handle 72 and flexible guide tube 74. Slidably received in the guide tube is a delivery tube 76 having the obturator 50 disposed at its distal end 78. A release means 80 is insertable in a proximal end 82 of the delivery tube 76 and by means of which the obturator 50 may be ejected from the end of the delivery tube. The guide tube is guided down the trachea and into the appropriate bronchus by means of guide lines (not shown) which enable the delivery system to be turned to follow the desired course. Optical guidance means may be included, or real-time X-ray or other monitoring methods may be employed to guide the surgeon. Once the end of the guide tube reaches the correct location, the delivery tube is inserted in the handle end of the delivery device 70, and then the release means 80 is pushed down the tube 76 to eject the obturator. The obturator is adapted to expand or be expanded, when ejected, to fill and block the tube or tubule in which it is inserted.
  • [0046]
    As can be seen from FIG. 3 a, the obturator 50 a in its first embodiment is comprised of two main components, a securing element in the form of a stent 90, and a blocking element in the form of a closed-cell, PVC foam plug 92.
  • [0047]
    The stent 90 is constructed from a plurality of legs 91 of surgical grade stainless steel wire welded together such that when extended the stent appears as a series 90 b of connected ‘W’s, as shown in an unconnected disposition in FIG. 3 c. Indeed, it is not essential that the final connection between ends 94,96 be made to form a closed crown arrangement (as shown in FIG. 3 a); it is equally effective merely to roll the stent 90 b as indicated by arrows in FIG. 3 c.
  • [0048]
    When the two ends of the stent are joined together, the stent 90 folds into a circular frame or crown, capable of encompassing the biocompatible block 92. The stent is constructed so as to be of a size slightly smaller (in its unstressed condition) than the block, so that its natural resilience squeezes the block slightly. On the other hand, the stent should be larger than the airway into which it is to be introduced so that it presses outwardly against the wall of the airway, and is incorporated into the mucosa of the air passage.
  • [0049]
    The legs 91 of the stent crown are fitted with both internal barbs 98 and external anchors 100. The barbs 98 embed themselves in the block 92 and secure the block to the stent 90. The anchors 100 are adapted to engage the walls of the patient's airways to hold the stent in position.
  • [0050]
    FIG. 4 a shows an internal barb 98. The internal barb, also constructed from surgical quality stainless steel, is substantially straight and has a hook 99 at one end. The hooked end 99 is the point and means by which the barb is secured to the biocompatible block.
  • [0051]
    FIG. 4 b shows an external anchor 100. The anchor, which is also constructed from surgical quality stainless steel, is again substantially straight and has a coil 101 at its end. A coil is used so that damage is not caused to the tissue of the airway in which the obturator is fitted, particularly if and when the obturator is removed.
  • [0052]
    The barbs and anchors are joined to the stent crown by a welded joint between two adjacent legs 91. Barbs can alternate with anchors at the same end of the stent, or one end can have all barbs, while the other end has all anchors. Both arrangements are shown in FIGS. 3 a and c respectively.
  • [0053]
    A different embodiment of obturator 50 b, also in accordance with the present invention, is shown in FIG. 3 b in which surgical quality stainless steel wires are all welded together at a point 104 to form a domed stent 90 b. Legs 91 b are alternately turned inwards to form barbs 98 b, or outwards to form anchors 100 b. Alternatively, all the legs could be anchors 100 b, with interspersed shorter barbs 98 bb, as one is shown in dashed lines in FIG. 3 b.
  • [0054]
    The aforementioned obturators all rely on resilience of the steel to return the stent to its original shape once released from the delivery mechanism and so as to enable fitment in a narrower tubule than the unstressed size of the stent would otherwise allow. However, this requires prestressing the stent and keeping it stressed during delivery. Thus the present invention may find suitable application for memory metals, which only return to their original shape when some physical condition changes, for example, temperature rise or electrical current flow.
  • [0055]
    It is essential for the blocking device 92 to be comprised of a resiliently deformable material such as PVC foam as mentioned above. This enables the blocking device to be easily surrounded by the stent 90 and deformed into a compact structure, thereby enabling delivery of the block to its destination in the lung.
  • [0056]
    It is likewise essential that the block be capable of expanding and reforming into its original shape once deposited in the desired location in the lungs. It should be noted that the block is deformed and reformed in both an axial and a radial direction. It is the block 92 which seals a bronchial tube or tubule; mucous surrounds the block and forms a fluid tight seal. The presence of the stent around the block does not inhibit sealing in any way since the stent is essentially incorporated into the mucosa lining the airway.
  • [0057]
    Under compression, PVC foam has a high coefficient of friction which would prevent ejection from the delivery device as described above, if it was not surrounded by the stent 90, which offers a relatively low friction surface to the inside of delivery tube 76.
  • [0058]
    However, it is feasible that the block 92 could include a low friction surface to enable such ejection without the stent. Instead of the stent as described above, anchor means might be moulded in biocompatible plastics material as a crown, for example, on one end of the block, and either be adhered, fused or otherwise bound thereto.
  • [0059]
    The effectiveness of the device depends, to some extent, on the length of the block. Moreover, the block is required to be of a size which is both comfortable to the patient once expanded in the lung and which expands to completely obstruct the passage of air into the affected portions of the lung. The extended size of the block therefore ranges between 5 mm and 25 mm in length, and between 5 and 11 mm in diameter, depending on the size of the tube or tubule to be obturated.
  • [0060]
    Obturator 50 c shown in FIG. 5, comprises a balloon 200, which is inflated after insertion and then detached. The balloon is captivated in an appropriate securing device such as stent 202. In this case, the barbs would not be sharp, but would merely retain ends of the balloon, or, as shown, would comprise turned-in points 204,206 at each end of the stent. Anchors 201 are provided.
  • [0061]
    Finally, as mentioned above, the obturator may be as shown at 50 d in FIG. 6, where it comprises a diaphragm 300 expanded by an internal stent 302 having anchors 302. One end 306 of the diaphragm is attached to the stent to retain it on the stent. The diaphragm is also adhered to the stent.
  • [0062]
    While the obturator and method of the present invention has been described with reference to human patients, animal patients may in certain circumstances also benefit.
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US2832078 *17 oct. 195629 avr. 1958Battelle Memorial InstituteHeart valve
US2981254 *12 nov. 195725 avr. 1961Vanderbilt Edwin GApparatus for the gas deflation of an animal's stomach
US3320972 *16 avr. 196423 mai 1967High Roy FProsthetic tricuspid valve and method of and device for fabricating same
US3445916 *19 avr. 196727 mai 1969Schulte Rudolf RMethod for making an anatomical check valve
US3657744 *8 mai 197025 avr. 1972Univ MinnesotaMethod for fixing prosthetic implants in a living body
US3671979 *23 sept. 196927 juin 1972Univ UtahCatheter mounted artificial heart valve for implanting in close proximity to a defective natural heart valve
US3788327 *30 mars 197129 janv. 1974Donowitz HSurgical implant device
US3874388 *12 févr. 19731 avr. 1975Ochsner Med Found AltonShunt defect closure system
US4014318 *22 mai 197529 mars 1977Dockum James MCirculatory assist device and system
US4056854 *28 sept. 19768 nov. 1977The United States Of America As Represented By The Department Of Health, Education And WelfareAortic heart valve catheter
US4084268 *22 avr. 197618 avr. 1978Shiley Laboratories, IncorporatedProsthetic tissue heart valve
US4086665 *16 déc. 19762 mai 1978Thermo Electron CorporationArtificial blood conduit
US4212463 *17 févr. 197815 juil. 1980Pratt Enoch BHumane bleeder arrow
US4218782 *19 mai 197826 août 1980Biocoating AnpartsselskabHeart valve prosthesis and method for the production thereof
US4222126 *14 déc. 197816 sept. 1980The United States Of America As Represented By The Secretary Of The Department Of Health, Education & WelfareUnitized three leaflet heart valve
US4250873 *17 avr. 197817 févr. 1981Richard Wolf GmbhEndoscopes
US4302854 *4 juin 19801 déc. 1981Runge Thomas MElectrically activated ferromagnetic/diamagnetic vascular shunt for left ventricular assist
US4339831 *27 mars 198120 juil. 1982Medtronic, Inc.Dynamic annulus heart valve and reconstruction ring
US4477930 *28 sept. 198223 oct. 1984Mitral Medical International, Inc.Natural tissue heat valve and method of making same
US4698294 *12 sept. 19866 oct. 1987E. I. Du Pont De Nemours And CompanyLamination of photopolymerizable film onto a substrate employing an intermediate nonphotosensitive liquid layer
US4710192 *17 oct. 19861 déc. 1987Liotta Domingo SDiaphragm and method for occlusion of the descending thoracic aorta
US4732152 *5 déc. 198522 mars 1988Medinvent S.A.Device for implantation and a method of implantation in a vessel using such device
US4759758 *7 déc. 198426 juil. 1988Shlomo GabbayProsthetic heart valve
US4774942 *28 août 19874 oct. 1988Litton Systems, Inc.Balanced exhalation valve for use in a closed loop breathing system
US4808183 *3 juin 198028 févr. 1989University Of Iowa Research FoundationVoice button prosthesis and method for installing same
US4819664 *17 févr. 198811 avr. 1989Stefano NazariDevice for selective bronchial intubation and separate lung ventilation, particularly during anesthesia, intensive therapy and reanimation
US4830003 *17 juin 198816 mai 1989Wolff Rodney GCompressive stent and delivery system
US4832680 *3 juil. 198623 mai 1989C.R. Bard, Inc.Apparatus for hypodermically implanting a genitourinary prosthesis
US4846836 *3 oct. 198811 juil. 1989Reich Jonathan DArtificial lower gastrointestinal valve
US4850999 *26 mai 198125 juil. 1989Institute Fur Textil-Und Faserforschung Of StuttgartFlexible hollow organ
US4877025 *6 oct. 198831 oct. 1989Hanson Donald WTracheostomy tube valve apparatus
US4879998 *6 mai 198814 nov. 1989Litton Systems, Inc.Balanced exhalation valve for use in a closed loop breathing system
US4934999 *28 juil. 198819 juin 1990Paul BaderClosure for a male urethra
US4946463 *10 avr. 19897 août 1990Pioneering Technologies, Inc.Vessel occluder
US4983177 *3 janv. 19908 janv. 1991Wolf Gerald LMethod and apparatus for reversibly occluding a biological tube
US4990151 *18 sept. 19895 févr. 1991Medinvent S.A.Device for transluminal implantation or extraction
US4994069 *2 nov. 198819 févr. 1991Target TherapeuticsVaso-occlusion coil and method
US5061274 *4 déc. 198929 oct. 1991Kensey Nash CorporationPlug device for sealing openings and method of use
US5116360 *27 déc. 199026 mai 1992Corvita CorporationMesh composite graft
US5116564 *10 oct. 198926 mai 1992Josef JansenMethod of producing a closing member having flexible closing elements, especially a heart valve
US5123919 *21 nov. 199123 juin 1992Carbomedics, Inc.Combined prosthetic aortic heart valve and vascular graft
US5147370 *12 juin 199115 sept. 1992Mcnamara Thomas ONitinol stent for hollow body conduits
US5151105 *7 oct. 199129 sept. 1992Kwan Gett CliffordCollapsible vessel sleeve implant
US5152770 *22 mars 19916 oct. 1992Ab HeparImplantable device for occluding a duct in the body of a living being
US5158548 *24 juil. 199127 oct. 1992Advanced Cardiovascular Systems, Inc.Method and system for stent delivery
US5161524 *2 août 199110 nov. 1992Glaxo Inc.Dosage inhalator with air flow velocity regulating means
US5246445 *24 janv. 199221 sept. 1993Instent Inc.Device for the treatment of constricted ducts in human bodies
US5306234 *23 mars 199326 avr. 1994Johnson W DudleyMethod for closing an atrial appendage
US5352240 *31 mai 19894 oct. 1994Promedica International, Inc.Human heart valve replacement with porcine pulmonary valve
US5358518 *25 janv. 199325 oct. 1994Sante CamilliArtificial venous valve
US5366478 *27 juil. 199322 nov. 1994Ethicon, Inc.Endoscopic surgical sealing device
US5382259 *26 oct. 199217 janv. 1995Target Therapeutics, Inc.Vasoocclusion coil with attached tubular woven or braided fibrous covering
US5382261 *1 sept. 199217 janv. 1995Expandable Grafts PartnershipMethod and apparatus for occluding vessels
US5392775 *22 mars 199428 févr. 1995Adkins, Jr.; Claude N.Duckbill valve for a tracheostomy tube that permits speech
US5409019 *3 nov. 199325 avr. 1995Wilk; Peter J.Coronary artery by-pass method
US5411507 *5 janv. 19942 mai 1995Richard Wolf GmbhInstrument for implanting and extracting stents
US5411552 *14 juin 19942 mai 1995Andersen; Henning R.Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
US5413599 *13 déc. 19939 mai 1995Nippon Zeon Co., Ltd.Medical valve apparatus
US5417226 *9 juin 199423 mai 1995Juma; SaadFemale anti-incontinence device
US5445626 *15 mai 199229 août 1995Gigante; LuigiValve operated catheter for urinary incontinence and retention
US5453090 *1 mars 199426 sept. 1995Cordis CorporationMethod of stent delivery through an elongate softenable sheath
US5486154 *8 juin 199323 janv. 1996Kelleher; Brian S.Endoscope
US5499995 *25 mai 199419 mars 1996Teirstein; Paul S.Body passageway closure apparatus and method of use
US5500014 *9 mai 199419 mars 1996Baxter International Inc.Biological valvular prothesis
US5562608 *13 avr. 19958 oct. 1996Biopulmonics, Inc.Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
US5588424 *28 juin 199531 déc. 1996The Cleveland Clinic FoundationBronchial blocker endotracheal apparatus
US5645519 *18 mars 19948 juil. 1997Jai S. LeeEndoscopic instrument for controlled introduction of tubular members in the body and methods therefor
US5645565 *13 juin 19958 juil. 1997Ethicon Endo-Surgery, Inc.Surgical plug
US5649906 *19 janv. 199522 juil. 1997Gory; PierreMethod for implanting a removable medical apparatus in a human body
US5658330 *25 avr. 199519 août 1997Mcghan Medical Corp.Molded silicone foam implant and method for making
US5660175 *21 août 199526 août 1997Dayal; BimalEndotracheal device
US5662713 *14 sept. 19952 sept. 1997Boston Scientific CorporationMedical stents for body lumens exhibiting peristaltic motion
US5683451 *7 juin 19954 nov. 1997Cardiovascular Concepts, Inc.Apparatus and methods for deployment release of intraluminal prostheses
US5697968 *10 août 199516 déc. 1997Aeroquip CorporationCheck valve for intraluminal graft
US5733329 *30 déc. 199631 mars 1998Target Therapeutics, Inc.Vaso-occlusive coil with conical end
US5755770 *31 janv. 199526 mai 1998Boston Scientific CorporatiionEndovascular aortic graft
US5803080 *20 déc. 19968 sept. 1998Willy Rusch AgInstrument for interventional flexible tracheoscopy/bronchoscopy
US5833707 *5 juil. 199510 nov. 1998Advanced Cardiovascular Systems, Inc.Removable stent and method of deployment
US5840081 *19 févr. 199724 nov. 1998Andersen; Henning RudSystem and method for implanting cardiac valves
US5855587 *22 août 19965 janv. 1999Chon-Ik HyonHole forming device for pierced earrings
US5855601 *21 juin 19965 janv. 1999The Trustees Of Columbia University In The City Of New YorkArtificial heart valve and method and device for implanting the same
US5868704 *26 juin 19969 févr. 1999W. L. Gore & Associates, Inc.Balloon catheter device
US5876445 *26 nov. 19962 mars 1999Boston Scientific CorporationMedical stents for body lumens exhibiting peristaltic motion
US5919224 *12 févr. 19976 juil. 1999Schneider (Usa) IncMedical device having a constricted region for occluding fluid flow in a body lumen
US6022312 *1 mai 19968 févr. 2000Chaussy; ChristianEndosphincter, set for releasable closure of the urethra and method for introduction of an endosphincter into the urethra
US6027508 *3 oct. 199622 févr. 2000Scimed Life Systems, Inc.Stent retrieval device
US6287290 *2 juil. 199911 sept. 2001PulmonxMethods, systems, and kits for lung volume reduction
US6398775 *21 oct. 19994 juin 2002PulmonxApparatus and method for isolated lung access
US6527761 *27 oct. 20004 mars 2003Pulmonx, Inc.Methods and devices for obstructing and aspirating lung tissue segments
US6585639 *27 oct. 20001 juil. 2003PulmonxSheath and method for reconfiguring lung viewing scope
US6709401 *2 juil. 200123 mars 2004PulmonxMethods, systems, and kits for lung volume reduction
US6878141 *28 juin 200012 avr. 2005PulmonxMethods systems and kits for lung volume reduction
US6997918 *4 mars 200314 févr. 2006PulmonxMethods and devices for obstructing and aspirating lung tissue segments
US20020062120 *13 déc. 200123 mai 2002PulmonxMethods, systems, and kits for lung volume reduction
US20020077593 *11 févr. 200220 juin 2002PulmonxApparatus and method for isolated lung access
US20040158228 *26 janv. 200412 août 2004PulmonxMethods, systems, and kits for lung volume reduction
US20050015106 *20 août 200420 janv. 2005PulmonxMethods, systems, and kits for lung volume reduction
US20050061322 *3 nov. 200424 mars 2005PulmonxMethod and arrangement for reducing the volume of a lung
US20050203483 *12 avr. 200515 sept. 2005PulmonxMethods, systems, and kits for lung volume reduction
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US768233230 juin 200423 mars 2010Portaero, Inc.Methods to accelerate wound healing in thoracic anastomosis applications
US768601312 févr. 200830 mars 2010Portaero, Inc.Variable resistance pulmonary ventilation bypass valve
US772630512 févr. 20081 juin 2010Portaero, Inc.Variable resistance pulmonary ventilation bypass valve
US77530526 févr. 200813 juil. 2010Portaero, Inc.Intra-thoracic collateral ventilation bypass system
US778908331 janv. 20087 sept. 2010Portaero, Inc.Intra/extra thoracic system for ameliorating a symptom of chronic obstructive pulmonary disease
US781127427 avr. 200412 oct. 2010Portaero, Inc.Method for treating chronic obstructive pulmonary disease
US782436610 déc. 20042 nov. 2010Portaero, Inc.Collateral ventilation device with chest tube/evacuation features and method
US78287897 avr. 20089 nov. 2010Portaero, Inc.Device and method for creating a localized pleurodesis and treating a lung through the localized pleurodesis
US78960086 août 20071 mars 2011Portaero, Inc.Lung reduction system
US790980318 févr. 200922 mars 2011Portaero, Inc.Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US792732418 févr. 200919 avr. 2011Portaero, Inc.Aspirator and method for pneumostoma management
US793164121 févr. 200826 avr. 2011Portaero, Inc.Visceral pleura ring connector
US802132020 sept. 2011Portaero, Inc.Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma
US80294927 avr. 20084 oct. 2011Portaero, Inc.Method for treating chronic obstructive pulmonary disease
US806231512 févr. 200822 nov. 2011Portaero, Inc.Variable parietal/visceral pleural coupling
US810447423 août 200531 janv. 2012Portaero, Inc.Collateral ventilation bypass system with retention features
US813652014 janv. 201020 mars 2012Pulmonx CorporationOcclusion device
US81365267 mars 200720 mars 2012Pulmonx CorporationMethods and devices to induce controlled atelectasis and hypoxic pulmonary vasoconstriction
US814245512 sept. 200827 mars 2012Pneumrx, Inc.Delivery of minimally invasive lung volume reduction devices
US815782317 avr. 2012Pneumrx, Inc.Lung volume reduction devices, methods, and systems
US81578372 juin 200617 avr. 2012Pneumrx, Inc.Minimally invasive lung volume reduction device and method
US816303421 févr. 200824 avr. 2012Portaero, Inc.Methods and devices to create a chemically and/or mechanically localized pleurodesis
US822046019 nov. 200417 juil. 2012Portaero, Inc.Evacuation device and method for creating a localized pleurodesis
US823158125 janv. 201131 juil. 2012Portaero, Inc.Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US825200318 févr. 200928 août 2012Portaero, Inc.Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US82826609 oct. 2012Pneumrx, Inc.Minimally invasive lung volume reduction devices, methods, and systems
US832323020 janv. 20104 déc. 2012Portaero, Inc.Methods and devices to accelerate wound healing in thoracic anastomosis applications
US833654012 févr. 200925 déc. 2012Portaero, Inc.Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease
US834218227 août 20071 janv. 2013Pulmonx CorporationFunctional assessment and treatment catheters and methods for their use in the lung
US83478808 janv. 2013Potaero, Inc.Pneumostoma management system with secretion management features for treatment of chronic obstructive pulmonary disease
US83478818 janv. 20108 janv. 2013Portaero, Inc.Pneumostoma management device with integrated patency sensor and method
US83489068 janv. 2013Portaero, Inc.Aspirator for pneumostoma management
US83571394 nov. 200822 janv. 2013Pulmonx CorporationMethods and devices for use in performing pulmonary procedures
US836572218 févr. 20095 févr. 2013Portaero, Inc.Multi-layer pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US843009418 févr. 200930 avr. 2013Portaero, Inc.Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US84536374 juin 2013Portaero, Inc.Pneumostoma management system for treatment of chronic obstructive pulmonary disease
US845363818 févr. 20094 juin 2013Portaero, Inc.One-piece pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US846470818 févr. 200918 juin 2013Portaero, Inc.Pneumostoma management system having a cosmetic and/or protective cover
US847444918 févr. 20092 juil. 2013Portaero, Inc.Variable length pneumostoma management system for treatment of chronic obstructive pulmonary disease
US84753898 juin 20102 juil. 2013Portaero, Inc.Methods and devices for assessment of pneumostoma function
US849160218 févr. 200923 juil. 2013Portaero, Inc.Single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US849600622 juin 201030 juil. 2013Pulmonx CorporationMethods and devices for passive residual lung volume reduction and functional lung volume expansion
US85065776 juil. 201213 août 2013Portaero, Inc.Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US851805311 févr. 201027 août 2013Portaero, Inc.Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US863260511 sept. 200921 janv. 2014Pneumrx, Inc.Elongated lung volume reduction devices, methods, and systems
US866870714 sept. 201211 mars 2014Pneumrx, Inc.Minimally invasive lung volume reduction devices, methods, and systems
US872173418 mai 201013 mai 2014Pneumrx, Inc.Cross-sectional modification during deployment of an elongate lung volume reduction device
US874092114 sept. 20123 juin 2014Pneumrx, Inc.Lung volume reduction devices, methods, and systems
US893231014 sept. 201213 janv. 2015Pneumrx, Inc.Minimally invasive lung volume reduction devices, methods, and systems
US898633829 oct. 200924 mars 2015Cook Biotech IncorporatedVascular plugs
US905009419 mars 20099 juin 2015Pulmonx CorporationMethods and devices for passive residual lung volume reduction and functional lung volume expansion
US917366911 sept. 20093 nov. 2015Pneumrx, Inc.Enhanced efficacy lung volume reduction devices, methods, and systems
US919240319 déc. 201324 nov. 2015Pneumrx, Inc.Elongated lung volume reduction devices, methods, and systems
US20040225254 *27 avr. 200411 nov. 2004Don TanakaLocalized pleurodesis chemical delivery
US20040237966 *20 mai 20042 déc. 2004Don TanakaMethods and devices to assist pulmonary decompression
US20040244803 *24 mai 20049 déc. 2004Don TanakaIntra-thoracic collateral ventilation bypass system
US20050025816 *30 juin 20043 févr. 2005Don TanakaMethods and devices to accelerate wound healing in thoracic anastomosis applications
US20060107961 *19 nov. 200425 mai 2006Don TanakaLocalized pleurodesis evacuation device
US20060118125 *19 nov. 20048 juin 2006Don TanakaPulmonary drug delivery
US20060118126 *19 nov. 20048 juin 2006Don TanakaMethods and devices for controlling collateral ventilation
US20060124126 *10 déc. 200415 juin 2006Don TanakaCollateral ventilation device with chest tube/evacuation features
US20070051372 *23 août 20058 mars 2007Don TanakaCollateral ventilation bypass system with retention features
US20070163598 *17 janv. 200619 juil. 2007Asia ChangVariable resistance pulmonary ventilation bypass valve
US20070225747 *7 mars 200727 sept. 2007PulmonxMethods and devices to induce controlled atelectasis and hypoxic pulmonary vasoconstriction
US20070270776 *6 août 200722 nov. 2007Respira, Inc.Lung reduction system
US20080051719 *27 août 200728 févr. 2008PulmonxFunctional assessment and treatment catheters and methods for their use in the lung
US20080072914 *24 août 200727 mars 2008Hendricksen Michael JBronchial Isolation Devices for Placement in Short Lumens
US20080188809 *7 avr. 20087 août 2008Portaero, Inc.Device and method for creating a localized pleurodesis and treating a lung through the localized pleurodesis
US20080221582 *4 mars 200811 sept. 2008PulmonxPulmonary stent removal device
US20080281151 *21 févr. 200813 nov. 2008Portaero, Inc.Pulmonary pleural stabilizer
US20080281433 *21 févr. 200813 nov. 2008Portaero, Inc.Methods and devices to create a chemically and/or mechanically localized pleurodesis
US20080283065 *21 févr. 200820 nov. 2008Portaero, Inc.Methods and devices to maintain patency of a lumen in parenchymal tissue of the lung
US20080295829 *21 févr. 20084 déc. 2008Portaero, Inc.Bridge element for lung implant
US20090012626 *2 juil. 20088 janv. 2009Pneumrx, Inc.Minimally invasive lung volume reduction devices, methods, and systems
US20090205641 *12 févr. 200920 août 2009Portaero, Inc.Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease
US20090205643 *18 févr. 200920 août 2009Portaero, Inc.Accelerated two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US20090205644 *18 févr. 200920 août 2009Portaero, Inc.Pneumostoma management system for treatment of chronic obstructive pulmonary disease
US20090205645 *18 févr. 200920 août 2009Portaero, Inc.Pneumostoma management method for the treatment of chronic obstructive pulmonary disease
US20090205646 *18 févr. 200920 août 2009Portaero, Inc.Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US20090205648 *18 févr. 200920 août 2009Portaero, Inc.Pneumostoma management system with secretion management features for treatment of chronic obstructive pulmonary disease
US20090205650 *18 févr. 200920 août 2009Portaero, Inc.Variable length pneumostoma management system for treatment of chronic obstructive pulmonary disease
US20090205651 *18 févr. 200920 août 2009Portaero, Inc.One-piece pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US20090205665 *18 févr. 200920 août 2009Portaero, Inc.Methods and devices for follow-up care and treatment of a pneumostoma
US20090209909 *18 févr. 200920 août 2009Portaero, Inc.Percutaneous single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US20090209924 *18 févr. 200920 août 2009Portaero, Inc.Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US20090209936 *18 févr. 200920 août 2009Portaero, Inc.Aspirator and method for pneumostoma management
US20090209971 *18 févr. 200920 août 2009Portaero, Inc.Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US20100070050 *18 mars 2010Pneumrx, Inc.Enhanced Efficacy Lung Volume Reduction Devices, Methods, and Systems
US20100100196 *11 sept. 200922 avr. 2010Pneumrx, Inc.Elongated Lung Volume Reduction Devices, Methods, and Systems
US20100106178 *29 oct. 200929 avr. 2010Obermiller F JosephVascular plugs
US20100129420 *20 janv. 201027 mai 2010Portaero, Inc.Methods and devices to accelerate wound healing in thoracic anastomosis applications
US20100147294 *19 févr. 201017 juin 2010Portaero, Inc.Devices and methods to maintain the patency of an opening relative to parenchymal tissue of the lung
US20100147295 *19 févr. 201017 juin 2010Portaero, Inc.Devices and methods to create and maintain the patency of an opening relative to parenchymal tissue of the lung
US20100158795 *28 mai 200924 juin 2010PulmonxMethods and systems for assessing lung function and delivering therapeutic agents
US20100170507 *8 janv. 20108 juil. 2010Portaero, Inc.Pneumostoma management device with integrated patency sensor and method
US20100204707 *11 févr. 201012 août 2010Portaero, Inc.Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US20100286544 *8 juin 201011 nov. 2010Portaero, Inc.Methods and devices for assessment of pneumostoma function
US20100305715 *18 mai 20102 déc. 2010Pneumrx, Inc.Cross-Sectional Modification During Deployment of an Elongate Lung Volume Reduction Device
US20110118669 *19 mai 2011Portaero, Inc.Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US20110152678 *23 juin 2011Pulmonx CorporationMethods and devices for passive residual lung volume reduction and functional lung volume expansion
Classifications
Classification aux États-Unis606/157, 623/23.7
Classification internationaleA61B17/24, A61F2/86, A61B17/12
Classification coopérativeA61B17/12177, A61B17/12104, A61B17/12022, A61B2017/1205, A61B17/12172, A61B17/12159, A61B17/12136
Classification européenneA61B17/12P7W1, A61B17/12P7B, A61B17/12P7W3, A61B17/12P7P, A61B17/12P5A, A61B17/12P
Événements juridiques
DateCodeÉvénementDescription
8 févr. 2007ASAssignment
Owner name: EMPHASYS MEDICAL, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SABANATHAN, THIRUMANI;BRADFORD HOSPITALS NHS TRUST;FOUNDRY, LLC, THE;REEL/FRAME:018880/0210
Effective date: 20010720
Owner name: FOUNDRY, LLC, THE, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SABANATHAN, THIRUMANI;BRADFORD HOSPITALS NHS TRUST;REEL/FRAME:018880/0051
Effective date: 20000606
Owner name: EMPHASYS MEDICAL, INC., CALIFORNIA
Free format text: SUPPLEMENT TO AGREEMENT OF JUNE 6, 2000.;ASSIGNOR:THIRUMANI SABANATHAN, BRADFORD HOSPITALS NHS TRUST AND THE FOUNDRY, LLC;REEL/FRAME:018880/0172
Effective date: 20010119
21 juin 2009ASAssignment
Owner name: PULMONX, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EMPHASYS MEDICAL, INC.;REEL/FRAME:022852/0851
Effective date: 20090331